🛡️ HUM $3.2M OTM Put Block Cross — Bearish/Hedge Lean, But the Cross Can't Prove It 🤝

📅 July 9, 2026 | 🔥 Unusual Activity Detected

✅ Updated July 10, 2026: the next-day OPRA open-interest snapshot confirms this trade OPENED — OI rose from 13 to 1,012 (+999), matching the trade size almost exactly. Direction and motive remain unproven. See the resolution below.

---

🎯 The Quick Take

Someone crossed 1,000 contracts of Humana's Nov 20, 2026 $360 puts at 14:44:22 ET today, paying $31.79 per contract for ≈$3.2M total premium — a strike sitting ≈9% below the $395.98 spot. This printed as a negotiated block cross (🤝), meaning a known counterparty took the other side off the lit book, not a sweep through the order book. That mechanism is important: it means we genuinely cannot prove whether this was a fresh bearish bet or a portfolio hedge — the print landed near the ask ($31.79 vs a $28.40/$31.80 quote), which is only a weak lean toward "someone paid up," nothing more. Translation: real downside insurance (or a real bearish bet) just got put on HUM ahead of a dense catalyst stretch — but who initiated it and why is unprovable from the tape alone.

---

📊 Company Overview

Humana Inc. (NYSE: HUM), headquartered in Louisville, Kentucky, is one of the largest U.S. health insurers and the market's most Medicare-Advantage-concentrated major payer:

• Market Cap: ≈$47.6B
• Sector / Industry: Healthcare — Managed Care / Health Insurance (Medicare Advantage focus)
• Current Price: ≈$395.98–$397.98 (up ≈68% over the trailing twelve months, recovering off 2025's utilization-shock lows)
• Trailing P/E: ≈41.9x — elevated versus managed-care peers, reflecting still-depressed trough earnings
• Primary Business: Individual and group Medicare Advantage, Part D prescription drug plans, Medicaid and specialty benefits (Insurance segment); pharmacy, home health, and senior primary-care clinics (CenterWell)

Because Medicare Advantage dominates its book, Humana is unusually sensitive to CMS rate notices, Star-Ratings quality bonuses, and senior medical-cost trends — all of which are directly in play over the life of this option.

---

💰 The Option Flow Breakdown

📊 What Just Happened

The Tape (July 9, 2026 @ 14:44:22 ET):

• 🤝 Mechanism: single-leg block cross — a broker matched a known buyer and known seller off the open book. This is a done deal between two counterparties, not aggression against the displayed market.
• 💸 Premium paid: ≈$3.2M ($31.79/contract × 1,000 contracts, or $31.79 × 100 shares × 1,000)
• 📏 Strike distance: $360 puts sit ≈9% below the $395.98 spot — meaningfully out-of-the-money
• 📊 Size vs. open interest: 1,000 contracts traded against prior OI of just 13 — that's ≈77x prior open interest, confirming this created brand-new contracts (a fresh open, not a close of an existing position)

✅ RESOLVED — Next-Day OI Confirms the Open (updated July 10, 2026)

The ≈06:30 ET OPRA open-interest snapshot for July 10 is in, and it landed within one contract of our projection.

Verdict: OPEN CONFIRMED, essentially perfectly. We projected ≈1,013; OI printed 1,012. A Δ of +999 against a trade size of 1,000 means virtually every contract in this block created brand-new open interest, with no transfer against pre-existing positions. 1,000 fresh November $360 puts now exist on Humana that did not exist before.

But the catch we flagged yesterday still stands: next-day OI resolves open-vs-close, not who's on which side of a cross. A block cross has a known buyer AND a known seller by definition. OI confirms a new position opened; it does not tell us whether the buyer or the seller initiated, or why. Treat the bearish/hedge framing below as a lean, not a fact — this OI confirmation does not upgrade it.

🤓 What This Actually Means — Plain English

Here's the plain-English decode of a long OTM put block cross:

• 🛡️ What was bought: the right to sell 100,000 shares of HUM at $360 anytime before November 20, 2026. If HUM is below $360 at expiration, this pays off; if HUM stays above $360, the entire $3.2M premium is lost.
• 🤝 Why "cross," not "sweep": a sweep rips through the displayed order book, screaming urgency. A cross is pre-negotiated — a desk found a counterparty willing to take the other side at an agreed price and printed it off-book. That's a calmer, less "panic" signal than a lit sweep, even though the dollar amount is real.
• 🎯 The weak bearish/hedge lean: the print landed near the ask side of a $28.40/$31.80 quote ($31.79). On a lit trade that would suggest an aggressive buyer; on a cross it's only a soft clue — the negotiated price could reflect either side's leverage in the deal, not genuine urgency. We're calling this "bearish/hedge-lean," not "confirmed bearish."
• 🏦 Two equally plausible stories:
  1. Portfolio hedge: someone holding a large long HUM stock or call position — HUM is up ≈68% over the past year — buys cheap-ish insurance 9% out of the money ahead of a stretch that includes Q2 earnings, the 2027 Star Ratings release, and Medicare's Annual Enrollment Period. This is "protect the gains" behavior, not a bet the stock crashes.
  2. Outright bearish bet: someone with no existing position simply thinks HUM's ≈42x trailing P/E on trough earnings, its still-elevated ≈91% benefit ratio, and its unresolved Star-Ratings litigation make a pullback likely — and is paying $3.2M to be right.
• ❓ What OPRA genuinely cannot tell us: the counterparty's identity, whether they hold offsetting HUM stock or calls, their cost basis, or their true motive. That's the honest limit of tape-only analysis on a cross.

Unusual score context: 1,000 contracts against 13 prior OI (≈77x) is a meaningfully outsized single print for HUM's options market — this is the kind of size you see a handful of times a year on this name, not routine daily flow.

---

📈 Technical Setup / Chart Check-Up

YTD Performance Chart

HUM has staged a strong recovery off its 2025 utilization-shock lows, up ≈68% over the trailing twelve months as the market began pricing in a margin-recovery story around the improved 2027 Medicare Advantage rate notice. The stock now trades at a rich ≈41.9x trailing P/E on still-depressed trough earnings — a valuation that leaves little room for a disappointing print.

Gamma-Based Support & Resistance Analysis

Current Price: ≈$397.76

• 🟠 $400 — nearest overhead resistance, only ≈0.6% away, and the single largest call-gamma level (0.40B) — a natural pin/ceiling near current price
• 🟠 $405 / $410 — secondary resistance rungs (0.20B and 0.12B call gamma) as price extends higher
• 🔵 $380 — the biggest two-sided gamma level on the board (0.48B put gamma + 0.46B call gamma), ≈4.5% below spot — this is the key structural pivot dealers are most positioned around
• 🔵 $395 / $375 / $365 — secondary put-gamma support shelves as price works lower
• ⚠️ $360 (the put strike itself) — relatively thin gamma (≈0.07B put gamma, ≈9.5% below spot) — meaning dealers aren't heavily defending this level. If HUM does crack the $380 pivot, a slide toward $360 wouldn't face much mechanical resistance, which is exactly the zone this put targets.

Net GEX bias: Call-dominant / bullish-leaning near-term (≈2.22B total call gamma vs ≈1.62B total put gamma) — dealer positioning still skews toward support-the-rally behavior close to spot, even as this new put sits well below the action.

Implied Move Analysis

Options market pricing (as of July 9, 2026, spot ≈$397.98):

• 📅 Weekly (Jul 10 – 1 day): ±$11.74 (±2.95%) → Range: $386.24 – $409.72
• 📅 Monthly OPEX (Jul 17 – 8 days): ±$28.28 (±7.11%) → Range: $369.70 – $426.26
• 📅 Quarterly Triple Witch (Sep 18 – 71 days): ±$90.38 (±22.71%) → Range: $307.60 – $488.36
• 📅 This trade's expiration (Nov 20 OPEX – 134 days): implied range ≈$280.84 – $515.12

Translation for regular folks: the options market is pricing a wide ≈$280–$515 range by this trade's November 20 expiration — a reflection of just how much event risk (earnings, Star Ratings, litigation) sits between now and then. Notice that the implied lower bound (≈$281) sits well below the $360 put strike, meaning the options market itself already assigns real odds to HUM trading meaningfully under $360 by expiration — this put isn't targeting a tail scenario, it's targeting a plausible one.

---

🎪 Catalysts

✅ Already Happened (Last ≈3 Months)

• Q1 2026 Earnings (April 29, 2026): Adjusted EPS of $10.31, at the high end of guidance, but management lowered FY2026 GAAP EPS guidance to "at least $8.36" from "at least $8.89" while affirming Adjusted EPS of "at least $9.00" [StockTitan].
• 2027 MA & Part D Final Rate Notice (April 6, 2026): CMS finalized a net average +2.48% year-over-year payment increase — a large upgrade from the +0.09% initially proposed, though Humana said it still falls short of what's needed and plans to adjust 2027 benefits.
• Star-Ratings Appeal Denied (April 14–15, 2026): CMS denied Humana's administrative appeal of its 2026 quality-bonus payment, following an earlier federal court loss now on appeal to the Fifth Circuit (filed Nov 26, 2025) — the case tied to an estimated $1B+ revenue hit [Healthcare Dive].

🔥 Upcoming Catalysts (Before Nov 20, 2026 Expiration)

• Q2 2026 Earnings — Wednesday, July 29, 2026 (results 6:00 a.m. ET, Q&A 8:00 a.m. ET) — the single most important near-term catalyst. Consensus EPS ≈$6.17, with the Insurance-segment benefit ratio (guided just above 91% for Q2, 92.75% ±25bps for FY) and any change to the "at least $9.00" adjusted-EPS floor as the key swing factors [Humana IR].
• 2027 Star Ratings Release — expected early-to-mid October 2026. The highest-magnitude catalyst before this option expires. Humana has publicly guided to a "meaningfully higher than 20%" share of members in 4-star+ plans and an "expected return to Top Quartile" — a positive surprise unwinds the current $1B+ quality-bonus drag, a miss extends it [Fierce Healthcare].
• Medicare 2027 Annual Enrollment Period (AEP) — Oct 15 to Dec 7, 2026. Humana's 2027 benefit cuts become visible to seniors here; early membership/retention signals are a real-time read on the reimbursement squeeze [SilverEdge].
• Fifth Circuit Star-Ratings appeal — no fixed date; any ruling or oral-argument scheduling is an event-driven wildcard that could land inside the window.
• Q3 2026 Earnings — expected late October / early November 2026 (not yet formally dated), likely the last scheduled catalyst before the Nov 20 expiration.

Important: the traded Nov 20, 2026 $360 put expires on a standard third-Friday OPEX date — that date itself is not a Humana event. The catalysts above are what will actually decide whether this put finishes in or out of the money.

---

🎲 Price Targets & Probabilities

Using the gamma map, implied-move data, and the catalyst calendar through the Nov 20 expiration:

📈 Bull Case (35% probability)

Target: $410–$430

A clean Q2 print affirming the "at least $9.00" adjusted-EPS floor, a favorable 2027 Star Ratings surprise ("return to Top Quartile" delivered), and stable-to-improving benefit ratio trends push HUM through the $400 gamma resistance toward the $426 monthly-OPEX implied-move upper bound and beyond. In this case, the $360 puts expire worthless — a 100% loss of the $3.2M premium.

🎯 Base Case (40% probability)

Target: $370–$405 (choppy, catalyst-driven range)

Q2 earnings roughly meet consensus, Star Ratings land in line with guidance (not a clean beat, not a disaster), and HUM chops between the $380 gamma pivot and $400 resistance while the market digests each catalyst individually. The puts likely retain modest time value but end up near or out of the money — a partial-to-total loss for the buyer, though the hedge (if that's what this is) did its job of capping tail risk.

📉 Bear Case (25% probability)

Target: $320–$360 (tests and breaks the put strike)

A weak Q2 print (benefit ratio above the 92.75% FY guide), a disappointing 2027 Star Ratings release that fails to deliver the guided "meaningfully higher than 20%" 4-star membership, or an adverse Fifth Circuit development reignites the $1B+ quality-bonus overhang. With thin gamma defense at $360, a break of the $380 pivot could slide quickly toward this zone — consistent with the implied-move lower bound of ≈$281 by November.

Put P&L in the bear case (illustrative, 1,000 contracts):

• HUM at $320 by Nov 20: puts worth $40.00, gain = $8.21/contract × 1,000 = ≈$821K profit (≈26% ROI)
• HUM at $300 by Nov 20: puts worth $60.00, gain = $28.21/contract × 1,000 = ≈$2.82M profit (≈89% ROI)
• HUM at $280 (near implied-move floor): puts worth $80.00, gain = $48.21/contract × 1,000 = ≈$4.82M profit (≈152% ROI)
• Breakeven: ≈$328.21 (≈17.1% below current spot) — HUM needs to fall by that much for the buyer to just get their premium back

---

💡 Four Ways to Read This Trade

🎰 YOLO Trader

Buying a handful of the exact same Nov 20 $360 puts to mirror this print is a pure bet that Q2 earnings or the Star Ratings release goes badly wrong. Premium is real money at real risk — 134 days of theta decay ahead of you, and you need HUM below the ≈$328 breakeven just to get whole. Risk level: EXTREME. Only size this as a lottery-ticket allocation you can lose entirely, and know you're betting against a stock that's up ≈68% over the past year and a call-dominant near-term gamma map.

🌊 Swing Trader

A tighter, defined-risk way to play the same bearish/hedge lean: watch how HUM reacts to the July 29 earnings print first. If the benefit ratio disappoints and HUM breaks the $380 gamma pivot, consider a put spread (e.g., buy the $380 put, sell the $360 put, same Nov 20 expiration) to target the thin-gamma zone this cross is already positioned in — cheaper than the outright put, with a defined max loss. Wait for confirmation rather than front-running the earnings binary.

💰 Premium Collector

If you think HUM's ≈68% run has priced in most of the good news and the stock consolidates through Q2 earnings and the October Star Ratings without a clean breakdown, selling cash-secured puts far below this cross's $360 strike (say, $320–$330, well past the implied-move floor) collects premium while leaving room for the stock to chop. You're effectively taking the other side of this trade's worst-case scenario, at a strike this desk didn't choose to buy protection at.

🌱 Beginner

Before touching HUM options, understand what actually happened here: a big trader paid $3.2M for insurance-like downside protection (or made a bearish bet — we genuinely can't tell which from a cross). That's not a green light to short the stock or buy puts yourself. If you're new to options, the safest way to engage with this story is simply watching — mark July 29 (Q2 earnings) and early-to-mid October (Star Ratings) on your calendar, see how the stock reacts, and use that as a real-world lesson in how binary catalysts move a name before you risk your own capital.

---

⚠️ Risk Factors — What the Tape Can't Prove

• 🤝 Cross mechanism = unprovable direction. This was a negotiated block with a known buyer and known seller by definition. We labeled it "bearish/hedge-lean" because the print landed near the ask, but that is a weak signal on a cross — not proof of aggression the way a lit sweep would be.
• 🏦 No counterparty visibility. OPRA data cannot tell us the broker, the trader's identity, whether they hold offsetting HUM stock or call positions, their cost basis, or any invisible hedge sitting outside the options market.
• ✅ Open confirmed, motive is not. The July 10 OI snapshot came in at 1,012, up from 13 (+999) — a fresh open, confirmed. It does not resolve whether the buyer was hedging gains or making a standalone bearish bet. That distinction remains genuinely unknowable from the public tape.
• ⚖️ Valuation cuts both ways. HUM's ≈41.9x trailing P/E is elevated versus peers, which supports the bear case — but it's elevated specifically because trough 2025 earnings understate normalized profitability, which supports the bull case too. Don't treat "expensive multiple" as a standalone sell signal.
• 📅 Binary-heavy calendar. Between now and Nov 20, HUM faces Q2 earnings (Jul 29), AEP open (Oct 15), the 2027 Star Ratings release (≈early-to-mid Oct), a likely Q3 print (late Oct/early Nov), and an open-ended Fifth Circuit appeal — any one of which can move the stock double digits independent of this option's thesis.
• 💸 Full-premium loss is the base-case risk for a naked put buyer. If HUM stays above $360 through Nov 20, 2026, the entire $3.2M premium (or your own smaller-scale mirror position) is lost — a common outcome for OTM options even when the directional read is correct but the magnitude or timing is off.

---

🎯 The Bottom Line

Real talk: A desk crossed $3.2M of Nov 20 $360 puts on Humana today — real size (≈77x prior open interest), a real strike 9% out of the money, and a real cluster of catalysts between now and expiration. But because it printed as a negotiated block cross, not a lit sweep, the honest verdict is: this is a confirmed fresh open with a weak bearish/hedge lean, not a confirmed bearish bet.

What this trade tells us:

• 🎯 Someone is willing to pay real money for downside exposure/protection on HUM specifically in the $360-and-below zone — a level with thin gamma defense that could see a fast move if the $380 pivot breaks
• 📅 The timing captures the entire near-term catalyst gauntlet: Q2 earnings (Jul 29), AEP (Oct 15), and the 2027 Star Ratings release (≈early-to-mid Oct) — arguably the single highest-stakes event for this name all year
• ⚖️ The implied-move math already assigns real probability to a sub-$360 outcome by November (lower bound ≈$281), so this isn't a tail-risk bet — it's positioned inside the market's own expected range

If you own HUM: this print is a reasonable prompt to think about your own downside protection heading into the July 29 print and the October Star Ratings release — not a reason to panic-sell a stock that's still up ≈68% over the past year.

If you're watching from the sidelines: don't front-run the earnings binary. Let July 29 clear, watch whether the $380 gamma pivot holds, and reassess before committing capital either direction.

If you're bearish: the thesis here (elevated benefit ratio, unresolved Star-Ratings litigation, a 2027 rate that management says still falls short) is coherent — but the risk/reward of chasing a fresh OTM put at these prices, 134 days from expiration, is a different question than agreeing with the direction.

Mark your calendar — key dates:

• 📅 July 29, 2026 — Q2 2026 earnings (before market, 6:00 a.m. ET)
• 📅 Early-to-mid October 2026 — 2027 Star Ratings release (highest-magnitude catalyst before expiration)
• 📅 October 15 – December 7, 2026 — Medicare AEP
• 📅 Late October / early November 2026 — likely Q3 2026 earnings
• 📅 November 20, 2026 — this trade's option expiration (standard OPEX, not a company event)

✅ Update (July 10, 2026): the OPRA open-interest snapshot is in — OI rose from 13 to 1,012 (+999), exactly as projected. The fresh open is confirmed. Direction and motive remain unproven, as a cross always leaves them.

Disclaimer: Options trading involves substantial risk of loss and is not suitable for all investors. This analysis is for educational purposes only and not financial advice. Past performance doesn't guarantee future results. This trade printed as a negotiated block cross — direction, counterparty identity, and true motive cannot be proven from the options tape alone. The bearish/hedge-lean framing in this article is an inference, not a fact. Always do your own research and consider consulting a licensed financial advisor before trading. Binary catalysts (earnings, regulatory decisions, litigation outcomes) can move HUM double digits in either direction with little warning.

---

About Humana Inc.: Humana is one of the largest U.S. health insurers and the market's most Medicare-Advantage-concentrated major payer, operating an Insurance segment (Medicare Advantage, Part D, Medicaid) alongside its CenterWell pharmacy, home health, and senior primary-care platform, with a market cap of ≈$47.6 billion in the Healthcare — Managed Care industry.

---

Last updated: July 10, 2026 — next-day OPRA open-interest snapshot resolved the open/close flag (OI 13 → 1,012, +999: OPEN CONFIRMED).